Adaptation of a chemosensitivity assay to accurately assess pemetrexed in ex vivo cultures of lung cancer

References

• Zhang GZ, Jiao SC, Meng ZT. Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients. J Exp Clin Cancer Res 2010; 29:38; http://dx.doi.org/10.1186/1756-9966-29-38; PMID: 20423465
   PubMed Web of Science ®Google Scholar
• Cancer Facts & Figures 2010. Available from URL: www.cancer.org/acs/groups/content/@nho/documents/document/acspc-024113.pdf [accessed February 7, 2011.
   Google Scholar
• Ho C, Davies AM, Lara PN Jr., Gandara DR. Second-line treatment for advanced-stage non-small-cell lung cancer: current and future options. Clin Lung Cancer 2006; 7:Suppl 4 S118 - 25; http://dx.doi.org/10.3816/CLC.2006.s.003; PMID: 16764752
   PubMed Web of Science ®Google Scholar
• Hu Z, Lin D, Yuan J, Xiao T, Zhang H, Sun W, et al. Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 2005; 11:4646 - 52; http://dx.doi.org/10.1158/1078-0432.CCR-04-2013; PMID: 16000556
   PubMed Web of Science ®Google Scholar
• Zucali PA, Ceresoli GL, De Vincenzo F, Simonelli M, Lorenzi E, Gianoncelli L, et al. Advances in the biology of malignant pleural mesothelioma. Cancer Treat Rev 2011; 37:543 - 58; http://dx.doi.org/10.1016/j.ctrv.2011.01.001; PMID: 21288646
   PubMed Web of Science ®Google Scholar
• Baratti D, Kusamura S, Deraco M. Diffuse malignant peritoneal mesothelioma: systematic review of clinical management and biological research. J Surg Oncol 2011; 103:822 - 31; http://dx.doi.org/10.1002/jso.21787; PMID: 21283990
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56:106 - 30; http://dx.doi.org/10.3322/canjclin.56.2.106; PMID: 16514137
   PubMed Web of Science ®Google Scholar
• Haber SE, Haber JM. Malignant mesothelioma: a clinical study of 238 cases. Ind Health 2011; 49:166 - 72; http://dx.doi.org/10.2486/indhealth.MS1147; PMID: 21173534
   PubMed Web of Science ®Google Scholar
• Ceresoli GL, Zucali PA, De Vincenzo F, Gianoncelli L, Simonelli M, Lorenzi E, et al. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer 2011; 72:73 - 7; http://dx.doi.org/10.1016/j.lungcan.2010.12.004; PMID: 21216487
   PubMed Web of Science ®Google Scholar
• Allen J, Jahanzeb M. Neoadjuvant chemotherapy in stage III NSCLC. J Natl Compr Canc Netw 2008; 6:285 - 93; PMID: 18377847
   PubMedGoogle Scholar
• Belli C, Anand S, Panella M, Giovannini M, Tassi G, Fennell D, et al. Will antiangiogenic agents be a future for mesothelioma therapy?. Curr Med Chem 2010; 17:3069 - 79; http://dx.doi.org/10.2174/092986710791959710; PMID: 20629625
   PubMed Web of Science ®Google Scholar
• Bech C, Sørensen JB. Chemotherapy induced pathologic complete response in malignant pleural mesothelioma: a review and case report. J Thorac Oncol 2010; 5:735 - 40; PMID: 20432521
   PubMed Web of Science ®Google Scholar
• Wakelee H, Belani CP. Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist 2005; 10:Suppl 3 1 - 10; http://dx.doi.org/10.1634/theoncologist.10-90003-1; PMID: 16368866
   PubMedGoogle Scholar
• Kindler HL. Systemic treatments for mesothelioma: standard and novel. Curr Treat Options Oncol 2008; 9:171 - 9; http://dx.doi.org/10.1007/s11864-008-0071-3; PMID: 18770046
   PubMed Web of Science ®Google Scholar
• Langer CJ, Besse B, Gualberto A, Brambilla E, Soria JC. The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol 2010; 28:5311 - 20; http://dx.doi.org/10.1200/JCO.2010.28.8126; PMID: 21079145
   PubMed Web of Science ®Google Scholar
• Rollins KD, Lindley C. Pemetrexed: a multitargeted antifolate. Clin Ther 2005; 27:1343 - 82; http://dx.doi.org/10.1016/j.clinthera.2005.09.010; PMID: 16291410
   PubMed Web of Science ®Google Scholar
• Adjei AA. Pharmacology and mechanism of action of pemetrexed. Clin Lung Cancer 2004; 5:Suppl 2 S51 - 5; http://dx.doi.org/10.3816/CLC.2004.s.003; PMID: 15117425
   PubMedGoogle Scholar
• Solomon B, Bunn PA Jr.. Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent. Future Oncol 2005; 1:733 - 46; http://dx.doi.org/10.2217/14796694.1.6.733; PMID: 16556051
   PubMedGoogle Scholar
• Calvert AH. Biochemical pharmacology of pemetrexed. Oncology (Williston Park) 2004; 18:Suppl 8 13 - 7; PMID: 15655931
   PubMedGoogle Scholar
• Nakagawa K, Kudoh S, Matsui K, Negoro S, Yamamoto N, Latz JE, et al. A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. Br J Cancer 2006; 95:677 - 82; http://dx.doi.org/10.1038/sj.bjc.6603321; PMID: 16940981
   PubMed Web of Science ®Google Scholar
• Sorenson JR, Wangila GW. Co-treatment with copper compounds dramatically decreases toxicities observed with cisplatin cancer therapy and the anticancer efficacy of some copper chelates supports the conclusion that copper chelate therapy may be markedly more effective and less toxic than cisplatin therapy. Curr Med Chem 2007; 14:1499 - 503; http://dx.doi.org/10.2174/092986707780831041; PMID: 17584059
   PubMed Web of Science ®Google Scholar
• Cohen MH, Johnson JR, Wang YC, Sridhara R, Pazdur R. FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist 2005; 10:363 - 8; http://dx.doi.org/10.1634/theoncologist.10-6-363; PMID: 15967829
   PubMed Web of Science ®Google Scholar
• Rusthoven JJ, Eisenhauer E, Butts C, Gregg R, Dancey J, Fisher B, et al, National Cancer Institute of Canada Clinical Trials Group. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 1999; 17:1194; PMID: 10561178
   PubMed Web of Science ®Google Scholar
• Ohe Y, Ichinose Y, Nakagawa K, Tamura T, Kubota K, Yamamoto N, et al. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res 2008; 14:4206 - 12; http://dx.doi.org/10.1158/1078-0432.CCR-07-5143; PMID: 18594001
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589 - 97; http://dx.doi.org/10.1200/JCO.2004.08.163; PMID: 15117980
   PubMed Web of Science ®Google Scholar
• Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P, Dingemans AM, et al. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2009; 27:2038 - 45; http://dx.doi.org/10.1200/JCO.2008.19.1650; PMID: 19307503
   PubMed Web of Science ®Google Scholar
• Bearz A, Garassino I, Cavina R, Favaretto A, Boccalon M, Talamini R, et al. Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study. Lung Cancer 2008; 60:240 - 5; http://dx.doi.org/10.1016/j.lungcan.2007.10.008; PMID: 18022729
   PubMed Web of Science ®Google Scholar
• Russo F, Bearz A, Pampaloni G, Investigators of Italian Pemetrexed Monotherapy of NSCLC Group. Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer. BMC Cancer 2008; 8:216; http://dx.doi.org/10.1186/1471-2407-8-216; PMID: 18667090
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Germonpré P, Bosquée L, Vansteenkiste J, Gervais R, Planchard D, et al. A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung Cancer 2010; 68:420 - 6; http://dx.doi.org/10.1016/j.lungcan.2009.07.011; PMID: 19692142
   PubMed Web of Science ®Google Scholar
• Zhao R, Zhang S, Hanscom M, Chattopadhyay S, Goldman ID. Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis. Clin Cancer Res 2005; 11:1294 - 301; PMID: 15709201
   PubMed Web of Science ®Google Scholar
• Backus HH, Pinedo HM, Wouters D, Padrón JM, Molders N, van Der Wilt CL, et al. Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates. Int J Cancer 2000; 87:771 - 8; http://dx.doi.org/10.1002/1097-0215(20000915)87:6<771::AID-IJC2>3.0.CO;2-V; PMID: 10956384
   PubMed Web of Science ®Google Scholar
• Müller C, Reddy JA, Leamon CP, Schibli R. Effects of the antifolates pemetrexed and CB3717 on the tissue distribution of (99m)Tc-EC20 in xenografted and syngeneic tumor-bearing mice. Mol Pharm 2010; 7:597 - 604; http://dx.doi.org/10.1021/mp900296k; PMID: 20199053
   PubMed Web of Science ®Google Scholar
• Worzalla JF, Shih C, Schultz RM. Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514. Anticancer Res 1998; 18:5A 3235 - 9; PMID: 9858888
   PubMed Web of Science ®Google Scholar
• Goldman ID, Zhao R. Molecular, biochemical, and cellular pharmacology of pemetrexed. Semin Oncol 2002; 29:Suppl 18 3 - 17; http://dx.doi.org/10.1016/S0093-7754(02)70040-7; PMID: 12571805
   PubMed Web of Science ®Google Scholar
• Zhao R, Matherly LH, Goldman ID. Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues. Expert Rev Mol Med 2009; 11:e4; http://dx.doi.org/10.1017/S1462399409000969; PMID: 19173758
   PubMed Web of Science ®Google Scholar
• Li KM, Rivory LP, Clarke SJ. Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules. Br J Cancer 2007; 97:1071 - 6; http://dx.doi.org/10.1038/sj.bjc.6603995; PMID: 17912246
   PubMed Web of Science ®Google Scholar
• Chattopadhyay S, Tamari R, Min SH, Zhao R, Tsai E, Goldman ID. Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability. Oncologist 2007; 12:808 - 15; http://dx.doi.org/10.1634/theoncologist.12-7-808; PMID: 17673612
   PubMed Web of Science ®Google Scholar
• Conrad DR. Vitamin B12 in Cell Culture. Available from URL: www.sigmaaldrich.com/life-science/cell-culture/learning-center/media-expert/vitamin-b12.html [accessed February 23, 2011].
   Google Scholar
• Brower SL, Fensterer JE, Bush JE. The ChemoFx assay: an ex vivo chemosensitivity and resistance assay for predicting patient response to cancer chemotherapy. Methods Mol Biol 2008; 414:57 - 78; PMID: 18175812
   PubMedGoogle Scholar
• Gallion H, Christopherson WA, Coleman RL, DeMars L, Herzog T, Hosford S, et al. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int J Gynecol Cancer 2006; 16:194 - 201; http://dx.doi.org/10.1111/j.1525-1438.2006.00301.x; PMID: 16445633
   PubMed Web of Science ®Google Scholar
• Mi Z, Holmes FA, Hellerstedt B, Pippen J, Collea R, Backner A, et al. Feasibility assessment of a chemoresponse assay to predict pathologic response in neoadjuvant chemotherapy for breast cancer patients. Anticancer Res 2008; 28:3B 1733 - 40; PMID: 18630452
   PubMed Web of Science ®Google Scholar
• Herzog TJ, Krivak TC, Fader AN, Coleman RL. Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer. Am J Obstet Gynecol 2010; 203:68 - , e1-6; http://dx.doi.org/10.1016/j.ajog.2010.01.059; PMID: 20227055
   PubMed Web of Science ®Google Scholar
• Suchy SL, Brower SL, Ervin PR. Methods for predicting a cancer patient's response to antifolate chemotherapy description/claims. In: USPTO, editor. U.S.A.: Precision Therapeutics, Inc. (Pittsburgh, PA, US), January 20, 2011.
   Google Scholar
• Messori A, Santarlasci B, Trippoli S, Vaiani M, Vacca F, Brutti MC. Clinical-economic appropriateness of drug treatments: designing a method that combines evidence-based information and cost assessments to construct league tables accounting for the potential number of patients. Expert Opin Pharmacother 2004; 5:2381 - 9; http://dx.doi.org/10.1517/14656566.5.11.2381; PMID: 15500385
   PubMed Web of Science ®Google Scholar
• Messori A, Trippoli S, Vaiani M. Efficacy, safety, and cost of new anticancer drugs. Price needs to be evaluated against effectiveness. BMJ 2002; 325:1302 - , author reply 1302; PMID: 12463189
   PubMed Web of Science ®Google Scholar
• Trippoli S, Messori A. Cost-effectiveness analyses of statistically ineffective treatments. JAMA 1998; 280:1992 - 3; http://dx.doi.org/10.1001/jama.280.23.1992-a; PMID: 9863846
   PubMed Web of Science ®Google Scholar
• Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003; 21:2651 - 7; http://dx.doi.org/10.1200/JCO.2003.12.004; PMID: 12860940
   PubMed Web of Science ®Google Scholar
• Tomek S, Emri S, Krejcy K, Manegold C. Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Br J Cancer 2003; 88:167 - 74; http://dx.doi.org/10.1038/sj.bjc.6600673; PMID: 12610498
   PubMed Web of Science ®Google Scholar
• Tan C, Treasure T. Mesothelioma: time to take stock. J R Soc Med 2005; 98:455 - 8; http://dx.doi.org/10.1258/jrsm.98.10.455; PMID: 16199813
   PubMed Web of Science ®Google Scholar
• Woodward RM, Brown ML, Stewart ST, Cronin KA, Cutler DM. The value of medical interventions for lung cancer in the elderly: results from SEER-CMHSF. Cancer 2007; 110:2511 - 8; http://dx.doi.org/10.1002/cncr.23058; PMID: 17955504
   PubMed Web of Science ®Google Scholar
• R1145 RPMI-1640 Medium. Available from URL: www.sigmaaldrich.com/catalog/ProductDetail.do?D7=0&N5=SEARCH_CONCAT_PNO%7CBRAND_KEY&N4=R1145%7CSIGMA&N25=0&QS=ON&F=SPEC [accessed February 1, 2011].
   Google Scholar